Previous 10 | Next 10 |
Gainers: Aclaris Therapeutics (NASDAQ: ACRS ) +68% . Avadel Pharmaceuticals plc (NASDAQ: AVDL ) +20% . BioCardia ( OTCQB:BCDA ) +15% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +14% . Earthstone Energy (NYSE: ESTE ) +14% . Pier 1 Imports (NYSE: PIR ) +15% . SunPower Corporation (...
Aclaris Therapeutics (NASDAQ: ACRS ) +73% on positive A-101 data . More news on: Aclaris Therapeutics, Inc., Capricor Therapeutics, Inc., Ocean Power Technologies, Inc., Stocks on the move, Read more ...
Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) were up 18% at 3:39 p.m. EDT on Monday in anticipation of the biotech presenting data on its diabetes drug Zynquista at the European Association for the Study of Diabetes (EASD) annual meeting tomorrow. Zynquista is an SGLT inhibitor des...
LXRX stock is making a big move this week, with a gain of over 75% this week after Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ended a collaboration agreement with Sanofi (NASDAQ:SNY). Sanofi News Gives Boost The pharmaceutical sector has been one of the most dynamic sectors for investo...
Shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) rose over 15% today and have gained about 90% in the last five days as investors continue to digest the fallout from a major partner walking away. On Sept. 10, the company and Sanofi terminated a collaboration to develop and commercia...
For a company that badly needed some good news, Lexicon Pharmaceuticals ' ( LXRX ) announcement of a settlement with now-former partner Sanofi ( SNY ) for its Zynquista SGLT-1/2 inhibitor is a welcome development. While the settlement, which returns full rights to the drug back to Lexicon a...
Gainers: Yuma Energy (NYSEMKT: YUMA ) +145% . T2 Biosystems (NASDAQ: TTOO ) +57% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +29% . Bicycle Therapeutics (NASDAQ: BCYC ) +25% . CARBO Ceramics (NYSE: CRR ) +23% . Luby's (NYSE: LUB ) +23% . CBL & Associates Properties (NYSE: CBL...
Yuma Energy (NYSEMKT: YUMA ) +69% announces third party purchase of senior secured bank debt. More news on: Yuma Energy, Inc., T2 Biosystems, Inc., Lexicon Pharmaceuticals, Inc., Stocks on the move, Read more ...
Lexicon Pharmaceuticals (NASDAQ: LXRX ) has officially regained all rights to diabetes med Zynquista (sotagliflozin) after its collaboration agreement with Sanofi (NASDAQ: SNY ) expired yesterday. More news on: Lexicon Pharmaceuticals, Inc., Sanofi, Healthcare stocks news, Read more ...
THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the termination of its alliance with Sanofi for the development and commercialization of Zynquista TM (sotagliflozin) and the settlement of its related disputes with S...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
INPEFA ® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study...
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...